ICU Medical (NASDAQ:ICUI) Insider Sells 2,250 Shares of Stock

August 13, 2026 by InsiderTrades.com

Key Points

ICU Medical insider Ben Sousa sold 2,250 shares for approximately $401,220, reducing his direct ownership by 42.25% to 3,076 shares.
The company exceeded quarterly expectations, reporting EPS of $2.37 versus the $1.91 consensus and revenue of $547.88 million versus estimates of $533.44 million.
Analyst sentiment remains positive, with a “Moderate Buy” consensus and an average price target of $192.80; institutional investors own approximately 96.1% of the stock.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) insider Ben Sousa sold 2,250 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total transaction of $401,220.00. Following the sale, the insider directly owned 3,076 shares of the company's stock, valued at approximately $548,512.32. This trade represents a 42.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

ICU Medical Stock Down 1.5%

Shares of NASDAQ ICUI opened at $179.34 on Thursday. ICU Medical, Inc. has a 12-month low of $110.50 and a 12-month high of $192.85. The company has a market cap of $4.48 billion, a P/E ratio of 151.98, a P/E/G ratio of 2.54 and a beta of 0.74. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The stock has a fifty day moving average price of $154.67 and a 200 day moving average price of $141.46.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company had revenue of $547.88 million for the quarter, compared to analysts' expectations of $533.44 million. During the same quarter in the previous year, the firm posted $2.10 earnings per share. The firm's quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Research analysts anticipate that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Jefferies Financial Group upgraded ICU Medical to a "strong-buy" rating in a report on Thursday, May 7th. Raymond James Financial reiterated a "strong-buy" rating and set a $200.00 price objective on shares of ICU Medical in a research note on Friday, August 7th. BTIG Research boosted their target price on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Wall Street Zen upgraded shares of ICU Medical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $192.80.

Read Our Latest Research Report on ICUI

ICU Medical News Summary

Here are the key news stories impacting ICU Medical this week:

Positive Sentiment: Strong earnings and margin expansion support the investment case. ICU Medical’s latest quarterly results exceeded expectations, with EPS of $2.37 versus the $1.91 consensus and revenue of $547.88 million versus estimates of $533.44 million. A recent analysis also highlighted margin expansion and strength in the company’s infusion systems business. ICUI Q2 Deep Dive: Margin Expansion and Infusion Systems Drive Outperformance
Positive Sentiment: Analysts raised price targets following the results. Needham lifted its target to $187, BTIG raised its target to $200, and Piper Sandler increased its target to $195 while maintaining an overweight rating. The consensus rating remains “Moderate Buy,” with an average price target of $192.80.
Neutral Sentiment: Institutional ownership remains high. Several smaller investment firms recently initiated or increased positions in ICU Medical, while institutional investors and hedge funds collectively own approximately 96.1% of the shares. The reported short-interest data showed zero shares short, offering little indication of short-selling pressure.
Negative Sentiment: Multiple insiders sold shares near recent highs. COO Christian B. Voigtlander sold 8,929 shares for approximately $1.63 million, CIO Ben Sousa sold 2,250 shares for about $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The sales reduced their respective holdings by approximately 19.3%, 42.3% and 7.2%, potentially raising investor concerns about insider conviction. Top ICU Medical Executive Makes a Notable Move With Company Stock

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Allworth Financial LP purchased a new position in ICU Medical in the second quarter valued at about $26,000. Hilton Head Capital Partners LLC purchased a new stake in ICU Medical during the 4th quarter worth approximately $32,000. Covestor Ltd raised its position in shares of ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 126 shares in the last quarter. Strs Ohio raised its position in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 146 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

About ICU Medical

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.